There’s a Fatty Liver Epidemic. AI Could Help Get Ahead of It

One billion fatty livers. That’s not a statistic—it’s a silent crisis waiting to topple. Fatty liver disease creeps up without symptoms until it doesn’t. Enter AI: not a cure, but an early-warning sensor. Models trained on standard clinical data can flag subclinical disease long before a doctor would think to look. That’s not a nice-to-have; it’s the only scalable triage for an epidemic outgrowing our clinicians. What this story truly signals is AI maturing past its obsession with rare, glamorous cancers. The biggest wins will come from unsexy, high-prevalence conditions like this. It’s a fundamental shift from reaction to prevention—AI as a chronic-disease sentinel. Pair that with expanding access to low-resource regions, and you get a genuine shot at flattening a curve that’s currently spiking out of control. The stakes are clear: AI won’t replace the hepatologist, but it will make them brutally more effective by surfacing the right patients at the right moment. In an epidemic that thrives on silence, that’s not just innovation—it’s intervention before the damage becomes irreversible. The liver whispers; AI can turn that into a shout. We’d better listen. ```json {"key_insight":"AI's greatest near-term impact is in preventive, high-prevalence diseases—not rare conditions—where